Hypoxia‑mediated activation of autophagic flux inhibits apoptosis of keratinocytes via blocking tumor necrosis factor‑related apoptosis‑inducing ligand

Kim,Sung‑Wook; Park,Sang‑Youel

doi:10.3892/mmr.2015.4592

Hypoxia‑mediated activation of autophagic flux inhibits apoptosis of keratinocytes via blocking tumor necrosis factor‑related apoptosis‑inducing ligand

Authors:
- Sung‑Wook Kim
- Sang‑Youel Park
View Affiliations

Affiliations: Department of Biochemistry, Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Jeonju, Jeonbuk 561‑756, Republic of Korea
Published online on: November 20, 2015 https://doi.org/10.3892/mmr.2015.4592
Pages: 805-810

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL) is toxic against transformed tumor cells. Cornification is the terminal differentiation of keratinocytes and a specific form of programmed cell death caused by TRAIL that occurs in keratinocytes. Apoptosis can also be triggered when TRAIL induces expression of keratinocyte differentiation markers. The present study reported that hypoxia inhibits TRAIL‑induced apoptosis due to autophagic flux. It is well known that hypoxia activates autophagy in keratinocytes and reduces p62 protein levels. The present study demonstrated that hypoxia inhibited TRAIL‑mediated apoptosis and induced autophagic flux in HaCaT cells. In addition, autophagic flux‑inactivating reagents, including 3‑methyladenine and chloroquine, increased the TRAIL sensitivity of HaCaT cells exposed to hypoxia. In conclusion, these results indicated that inactivating autophagy increased TRAIL sensitivity in hypoxic HaCaT cells. Autophagy inhibitors may be beneficial in therapies using TRAIL against skin cancers.

View Figures

View References

1	Johnstone RW, Frew AJ and Smyth MJ: The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer. 8:782–798. 2008. View Article : Google Scholar : PubMed/NCBI
2	Wu NL, Lee TA, Tsai TL and Lin WW: TRAIL-induced keratinocyte differentiation requires caspase activation and p63 expression. J Invest Dermatol. 131:874–883. 2011. View Article : Google Scholar : PubMed/NCBI
3	Li JH, Kirkiles-Smith NC, McNiff JM and Pober JS: TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol. 171:1526–1533. 2003. View Article : Google Scholar : PubMed/NCBI
4	Semenza GL: Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease. Pediatr Res. 49:614–617. 2001. View Article : Google Scholar : PubMed/NCBI
5	Hu Y, Kirito K, Yoshida K, Mitsumori T, Nakajima K, Nozaki Y, Hamanaka S, Nagashima T, Kunitama M, Sakoe K and Komatsu N: Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Mol Cancer Ther. 8:2329–2338. 2009. View Article : Google Scholar : PubMed/NCBI
6	Kaelin WG Jr: Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer. 115(Suppl 10): S2262–S2272. 2009. View Article : Google Scholar
7	Tandara AA and Mustoe TA: Oxygen in wound healing-more than a nutrient. World J Surg. 28:294–300. 2004. View Article : Google Scholar : PubMed/NCBI
8	LaVan FB and Hunt TK: Oxygen and wound healing. Clin Plast Surg. 17:463–472. 1990.PubMed/NCBI
9	Evans NT and Naylor PF: The systemic oxygen supply to the surface of human skin. Respir Physiol. 3:21–37. 1967. View Article : Google Scholar : PubMed/NCBI
10	Stewart FA, Denekamp J and Randhawa VS: Skin sensitization by misonidazole: a demonstration of uniform mild hypoxia. Br J Cancer. 45:869–877. 1982. View Article : Google Scholar : PubMed/NCBI
11	Stucker M, Struk A, Altmeyer P, Herde M, Baumgärtl H and Lübbers DW: The cutaneous uptake of atmospheric oxygen contributes significantly to the oxygen supply of human dermis and epidermis. J Physiol. 538:985–994. 2002. View Article : Google Scholar : PubMed/NCBI
12	Pursiheimo JP, Rantanen K, Heikkinen PT, Johansen T and Jaakkola PM: Hypoxia-activated autophagy accelerates degradation of SQSTM1/p62. Oncogene. 28:334–344. 2009. View Article : Google Scholar
13	Levine B and Kroemer G: Autophagy in the pathogenesis of disease. Cell. 132:27–42. 2008. View Article : Google Scholar : PubMed/NCBI
14	Delgado MA, Elmaoued RA, Davis AS, Kyei G and Deretic V: Toll-like receptors control autophagy. EMBO J. 27:1110–1121. 2008. View Article : Google Scholar : PubMed/NCBI
15	Hussey S, Travassos LH and Jones NL: Autophagy as an emerging dimension to adaptive and innate immunity. Semin Immunol. 21:233–241. 2009. View Article : Google Scholar : PubMed/NCBI
16	Zhao Y, Zhang CF, Rossiter H, Eckhart L, König U, Karner S, Mildner M, Bochkov VN, Tschachler E and Gruber F: Autophagy is induced by UVA and promotes removal of oxidized phospho-lipids and protein aggregates in epidermal keratinocytes. J Invest Dermatol. 133:1629–1637. 2013. View Article : Google Scholar : PubMed/NCBI
17	Lee HM, Shin DM, Yuk JM, Shi G, Choi DK, Lee SH, Huang SM, Kim JM, Kim CD, Lee JH and Jo EK: Autophagy negatively regulates keratinocyte inflammatory responses via scaffolding protein p62/SQSTM1. J Immunol. 186:1248–1258. 2011. View Article : Google Scholar
18	Seo JS, Seol JW, Moon MH, Jeong JK, Lee YJ and Park SY: Hypoxia protects neuronal cells from human prion protein fragment-induced apoptosis. J Neurochem. 112:715–722. 2010. View Article : Google Scholar
19	Candi E, Rufini A, Terrinoni A, Dinsdale D, Ranalli M, Paradisi A, De Laurenzi V, Spagnoli LG, Catani MV, Ramadan S, et al: Differential roles of p63 isoforms in epidermal development: selective genetic complementation in p63 null mice. Cell Death Differ. 13:1037–1047. 2006. View Article : Google Scholar : PubMed/NCBI
20	Eberle J, Fecker LF, Forschner T, Ulrich C, Röwert-Huber J and Stockfleth E: Apoptosis pathways as promising targets for skin cancer therapy. Br J Dermatol. 156(Suppl 3): 18–24. 2007. View Article : Google Scholar : PubMed/NCBI
21	Mora R, Abschuetz A, Kees T, Dokic I, Joschko N, Kleber S, Geibig R, Mosconi E, Zentgraf H, Martin-Villalba A and Régnier-Vigouroux A: TNF-alpha- and TRAIL-resistant glioma cells undergo autophagy-dependent cell death induced by activated microglia. Glia. 57:561–581. 2009. View Article : Google Scholar
22	Herrero-Martín G, Høyer-Hansen M, García-García C, Fumarola C, Farkas T, López-Rivas A and Jäättelä M: TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J. 28:677–685. 2009. View Article : Google Scholar : PubMed/NCBI
23	Itakura E and Mizushima N: p62 Targeting to the autophagosome formation site requires self-oligomerization but not LC3 binding. J Cell Biol. 192:17–27. 2011. View Article : Google Scholar : PubMed/NCBI
24	Singh K, Sharma A, Mir MC, Drazba JA, Heston WD, Magi-Galluzzi C, Hansel D, Rubin BP, Klein EA and Almasan A: Autophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin). Mol Cancer. 13:702014. View Article : Google Scholar : PubMed/NCBI